Price movement over the last 24 hours
Agilent Technologies Inc vs Royal Caribbean Cruises Ltd — how do they compare? Agilent Technologies Inc trades at $129.02 (market cap $37.04B), while Royal Caribbean Cruises Ltd trades at $281.95 (market cap $75.70B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 2× Agilent Technologies Inc's market cap, and Royal Caribbean Cruises Ltd pays the higher dividend (1.77%). Which is the better fit depends on your goals.
| A | RCL | |
|---|---|---|
Market Cap | $37.04B | $75.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $365.84 |
52-Week Low | $110.24 | $246.71 |
Enterprise Value | $38.59B | $96.98B |
Dividend Yield | 0.78% | 1.77% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Royal Caribbean (RCL) trades at $282.26, down 4.74% on the day, showing bearish technical momentum but maintaining strong fundamentals. The company reported robust Q1 2026 earnings of $3.60 per share, beating expectations, with revenue growth accelerating from $16.5B in 2024 to $17.9B in 2025. Analyst consensus remains positive with a $325.10 price target, though technical indicators signal near-term caution with support at $283.
RCL presents a compelling investment case with strong profitability (50.41% ROE) and consistent earnings beats, though elevated debt levels and fuel cost sensitivity pose risks. The stock's current pullback near key support levels offers potential entry points for long-term investors seeking exposure to the recovering cruise industry with disciplined financial management.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →